metaPreg - Vigabatrin (All indications) during pregnancy

Vigabatrin (All indications) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	6.04 [1.59, 23.00]	0%	5 studies	49,624	21	not evaluable	ROB	11.56 [2.55; .]
Major congenital malformations	6.04 [1.59, 23.00]	0%	5 studies	49,624	21	not evaluable	ROB	11.56 [2.55; .]
Microcephaly / Small head circumference for gestational age	1.81 [0.10, 31.40]	-	1 study	699	9	not evaluable	ROB	-
Congenital heart defects	12.98 [0.62, 271.33]	-	1 study	4	6	not evaluable	ROB	-
Digestive system anomalies	16.71 [0.77, 363.61]	-	1 study	3	6	not evaluable	ROB	-
Hypospadias	8.96 [0.45, 179.29]	-	1 study	6	6	not evaluable	ROB	-
Limb defects	23.44 [1.00, 547.07]	-	1 study	2	6	not evaluable	ROB	46.37 [1.07; .]
Neural Tube Defects	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
Oro-facial clefts	39.12 [1.43, 1070.14]	-	1 study	1	6	not evaluable	ROB	77.74 [2.21; .]
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.51 [0.03, 8.67]	-	1 study	383	13	not evaluable	ROB	-
Low birth weight (< 2500g)	1.24 [0.07, 21.50]	-	1 study	1,006	9	not evaluable	ROB	-
Small for gestational age (weight)	0.48 [0.03, 8.36]	-	1 study	2,416	9	not evaluable	ROB	-
Hide endpoints reported in only one study ...